ALLOS THERAPEUTICS (NASDAQ:ALTH)
6.16
-0 (-0%)
| ALLOS THERAPEUTICS (NASDAQ:ALTH) Delayed : |
| Previous Close |
$6.16 |
|
52 Week High |
$9.30 |
|
| Open |
$6.23 |
|
52 Week Low |
$4.68 |
| Day High |
$6.34 |
|
P/E |
N/A |
| Day Low |
$6.06 |
|
EPS |
$-0.78 |
| Volume |
1,013,249 |
|
|
|
| More ALTH Info:
Chart
SEC Filings
Profile
Historical
Options
|
View All ReportsStreetInsider.com Reports on ALTH
-
Nov 3, 2009 06:03 PM
After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
-
Nov 3, 2009 04:58 PM
Allos Therapeutics (ALTH) Reports Inline Q3 Loss of $0.21
-
Nov 2, 2009 01:40 PM
Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
-
Oct 13, 2009 04:08 PM
Allos Therapeutics (ALTH) Closes $93 Million Stock Offering
-
Oct 7, 2009 06:41 AM
Public Offering Price for Allos Therapeutics (ALTH) Announced
View All Reports
StreetInsider Reports on ALTH by Category
Comments on recent ALTH articles
Comments on ALTH
No comments are currently available.
on Nov 13, 2009
at 03:55 PM ANDREW OLIVER SATCHELL EXCELLENT
Article: Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
on Sep 25, 2009
at 10:33 AM PRICE CHANGE ARE DAY TRADERS AFTER THIS STOCK?
Article: Shares of Allos Therapeutics (ALTH) Give Back After Strong Opening
on Sep 1, 2009
at 07:58 PM Allos It looks good to me on approval....calls on this stock are looking 10 and 12.50.....if approved opens the drug up to alot more trials and hopefully a success in the fight against cancer
Article: Citi Maintains a 'Buy' on Allos Therapeutics (ALTH), Impressive Durability of Response Shown for PDX in PTCL
on Dec 8, 2008
at 02:24 PM Genworth There is news driving the price change. State ins. regulators meeting in Tx. have agreed to lower Capital funding requirements. Do your homework before posting info.
Article: Unusual 11 Mid-Day Movers 12/08: GNW, DRYS, PLD, TBSI Higher; ALTH, LSI, CBST, HL Lower
on Feb 20, 2008
at 03:42 PM INSM A $3.00 dollar stock trading below a $1.00.
Article: Analyst Call of the Year: Collins Stewart on Encysive (ENCY)